No approved hantavirus vaccine exists as of August 2026, with candidates limited to early-phase DNA platforms targeting Gn-Gc glycoproteins or preclinical mRNA and subunit designs against Andes and Hantaan strains. The 94.5% market-implied probability of no FDA approval by year-end reflects the absence of Phase 3 efficacy trials, the pathogen’s low incidence complicating large-scale human testing, and standard regulatory timelines requiring years of safety and immunogenicity data. Recent 2026 outbreaks have prompted modest NIH and EU funding increases plus new animal-model neutralizing antibody results, yet these advances remain distant from licensure. Accelerated emergency use authorization or rapid Phase 3 initiation from ongoing Phase 1/2 studies could narrow the gap, though such pathways lack precedent for this rodent-borne orthohantavirus.